Mastering CMC for Biologics: IND to BLA |EMA| FDA | PMDA |

In this lecture, you will build a strong foundation in biologics by understanding what biologic medicines are and how they differ from conventional small-molecule drugs. We will explore the major classes of biologics, including monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, antibody-drug conjugates (ADCs), and emerging therapeutic modalities.

You will also learn the unique characteristics of biologics, their manufacturing complexity, quality attributes, and why Chemistry, Manufacturing, and Controls (CMC) plays a critical role throughout product development and commercialization.

By the end of this lecture, you will have a clear understanding of the biologics landscape and the scientific and regulatory principles that form the foundation for the remainder of this course.

Monoclonal antibodies (mAbs) are the most successful class of biologic medicines and serve as the ideal model for understanding Biologics Chemistry, Manufacturing, and Controls (CMC). In this section, you will learn the scientific principles that underpin monoclonal antibody development and why mAbs have become the benchmark for modern biologic product development.

We begin by comparing biologics with conventional small-molecule drugs, highlighting the unique characteristics of biologics, including their complex molecular structure, production using living cells, inherent heterogeneity, and sensitivity to manufacturing and storage conditions. Building on this foundation, you will explore monoclonal antibody structure, mechanisms of action, therapeutic applications, and the key quality attributes that influence product safety, efficacy, and regulatory approval.

This section establishes the fundamental knowledge required for subsequent topics, including cell line development, manufacturing, analytical characterization, control strategy, comparability, stability, biosimilars, and global regulatory submissions. Understanding monoclonal antibodies as a model biologic will provide the scientific and regulatory framework needed to confidently navigate the complete biologics development lifecycle from IND to BLA.

In this section, you will gain a comprehensive understanding of the end-to-end manufacturing process of monoclonal antibodies, from cell culture to the final drug product. We begin by exploring the overall manufacturing workflow before examining upstream and downstream processing, including cell culture, harvesting, purification, viral clearance, and polishing steps.

The section also covers formulation and fill-finish operations, the role of critical excipients in biologic formulations, and the factors that influence product quality, stability, and patient safety. By the end of this section, you will understand how each manufacturing step contributes to producing a safe, effective, and high-quality biologic product while meeting global regulatory expectations.

This section focuses on building a robust manufacturing process using Quality by Design (QbD) principles and lifecycle process validation. You will learn how regulatory agencies expect manufacturers to develop scientifically sound processes through risk assessment, process understanding, critical quality attributes (CQAs), critical process parameters (CPPs), and integrated control strategies.

The section also explains the stages of process validation, continued process verification, and the application of lifecycle management principles to ensure consistent product quality throughout commercial manufacturing. By the end of this section, you will understand how QbD and process validation form the foundation of successful Biologics CMC development and global regulatory submissions.

Cell banking is the foundation of biologics manufacturing, ensuring a consistent, well-characterized, and reliable source of cells throughout the product lifecycle. In this section, you will develop a comprehensive understanding of cell banking principles and their critical role in maintaining product quality, safety, and manufacturing consistency.

You will begin by learning the fundamentals of cell banking and the global regulatory framework governing cell bank establishment, qualification, and testing. The section then explains the complete cell bank lifecycle, including Research Cell Bank (RCB), Master Cell Bank (MCB), Working Cell Bank (WCB), and End of Production Cell Bank (EOPCB), along with their specific purposes during biologics development and commercial manufacturing.

In addition, you will explore characterization and testing strategies, including identity, purity, genetic stability, adventitious agent testing, and regulatory expectations. The section concludes with interactive case studies, practical CMC implementation advice, and key regulatory insights that will help you confidently apply cell banking concepts in real-world biologics development and global regulatory submissions.

Comprehensive characterization is one of the most critical components of Biologics CMC and forms the scientific foundation for product development, control strategy, comparability, and regulatory approval. In this section, you will learn why extensive molecular characterization is essential for demonstrating the identity, quality, safety, and efficacy of biologic products.

The section begins with the global regulatory framework governing biologics characterization, followed by an explanation of why characterization is central to every stage of product development—from early research through commercial manufacturing and lifecycle management. You will then explore a systematic characterization strategy, including physicochemical, structural, biological, immunochemical, and purity assessments used to establish a comprehensive understanding of the product.

By the end of this section, you will understand how characterization data support Critical Quality Attribute (CQA) identification, specification setting, process development, comparability studies, biosimilar development, and successful global regulatory submissions. This knowledge will provide the foundation for many advanced CMC topics covered later in the course.

An effective control strategy is built on scientific understanding developed throughout the product lifecycle. In this section, you will learn how process knowledge, product characterization, analytical data, and risk assessment are integrated to establish a robust control strategy that consistently delivers high-quality biologic products.

You will explore the principles of process characterization, analytical characterization, and specification setting, and understand how each contributes to defining Critical Quality Attributes (CQAs) and ensuring process consistency. The section also provides a comprehensive discussion of comparability studies, demonstrating how manufacturing changes are scientifically evaluated while maintaining product quality, safety, and efficacy.

Finally, you will learn lifecycle management strategies through practical case studies, showing how integrated control strategies support post-approval changes, continuous improvement, global regulatory submissions, and successful CMC lifecycle management. By the end of this section, you will understand how science and regulatory expectations come together to build a comprehensive control strategy for modern biologics.

Stability is a critical component of biologics development, directly influencing product quality, shelf life, storage conditions, and regulatory approval. In this section, you will gain a comprehensive understanding of biologics stability programs, including global regulatory expectations from ICH Q5C and ICH Q1A, long-term and accelerated stability studies, forced degradation and stress testing, and in-use stability assessments.

You will also learn how compatibility studies, extractables and leachables (E&L), shipping qualification, and transport validation contribute to maintaining product quality throughout the supply chain. In addition, the section discusses common regulatory Information Requests (IRs) related to stability and practical strategies for preparing robust stability packages for IND, BLA, MAA, J-NDA and other global submissions. By the end of this section, you will be able to design, interpret, and defend stability programs from both scientific and regulatory perspectives.

The Common Technical Document (CTD) is the global standard for regulatory submissions to agencies such as the FDA, EMA, PMDA, and many other health authorities. In this section, you will develop a clear understanding of the ICH M4 CTD framework and learn how information is organized across Modules 1 through 5.

You will explore the purpose and content of each CTD module, understand the relationship between the Quality Overall Summary (Module 2) and the detailed CMC information presented in Module 3, and learn how nonclinical and clinical information fits within the overall submission. By the end of this section, you will be able to confidently navigate the CTD structure and understand where different types of information belong when preparing global IND, IMPD, BLA, NDA, MAA, and JNDA submissions.

CTD Module 3 is the foundation of every successful biologics regulatory submission. In this section, you will learn how to prepare a high-quality CMC dossier by understanding not only what regulators expect, but also why they expect it. The course takes a stage-by-stage approach from Pre-IND through BLA, demonstrating how CMC documentation evolves throughout product development.

You will learn practical strategies for planning CMC development, organizing scientific data, writing clear and effective Module 3 sections, and avoiding common submission deficiencies. The section also explains how Chemistry, Manufacturing, and Controls (CMC) information supports product quality, process understanding, regulatory compliance, and successful approvals. By the end of this section, you will be able to confidently contribute to CTD Module 3 authoring, review, and global regulatory submissions using a science- and risk-based approach.